Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · IEX Real-Time Price · USD
1.160
-0.050 (-4.13%)
May 2, 2024, 4:00 PM EDT - Market closed
Protalix BioTherapeutics Revenue
In the year 2023, Protalix BioTherapeutics had annual revenue of $65.49M with 37.48% growth. Revenue in the quarter ending December 31, 2023 was $10.49M with 21.69% year-over-year growth.
Revenue (ttm)
$65.49M
Revenue Growth
+37.48%
P/S Ratio
1.29
Revenue / Employee
$314,875
Employees
208
Market Cap
84.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
Dec 31, 2019 | 54.69M | 20.45M | 59.73% |
Dec 31, 2018 | 34.24M | 13.16M | 62.44% |
Dec 31, 2017 | 21.08M | 11.88M | 129.13% |
Dec 31, 2016 | 9.20M | 4.84M | 110.79% |
Dec 31, 2015 | 4.36M | 841.00K | 23.87% |
Dec 31, 2014 | 3.52M | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 34.42M | 31.46M | 1,059.84% |
Dec 31, 2011 | 2.97M | -8.28M | -73.60% |
Dec 31, 2010 | 11.24M | 10.86M | 2,797.94% |
Dec 31, 2009 | 388.00K | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 150.00K | -280.00K | -65.12% |
Dec 31, 2004 | 430.00K | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 0 | - | - |
Dec 31, 2000 | 0 | - | - |
Dec 31, 1999 | 3.55M | -4.48M | -55.76% |
Dec 31, 1998 | 8.04M | - | - |
Dec 31, 1997 | 0 | - | - |
Nov 30, 1996 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.11B |
PetMed Express | 276.97M |
Assertio Holdings | 152.07M |
BrainsWay | 31.79M |
Gritstone bio | 16.34M |
Armata Pharmaceuticals | 4.53M |
Milestone Pharmaceuticals | 1.00M |
Barinthus Biotherapeutics | 802.00K |
PLX News
- 7 weeks ago - Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results - PRNewsWire
- 2 months ago - Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 - PRNewsWire
- 2 months ago - Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference - PRNewsWire
- 4 months ago - Protalix BioTherapeutics Issues 2024 Letter to Stockholders - PRNewsWire
- 6 months ago - Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results - PRNewsWire
- 6 months ago - Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 - PRNewsWire
- 7 months ago - These Israeli pharmaceutical stocks are down in the wake of Hamas attack - Market Watch
- 7 months ago - Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel - PRNewsWire